A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Trial Profile

A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs TXH-TS01 (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 10 Aug 2017 According to a Therapix Biosciences media release, the company is planning conduct this trial at the Hannover Medical School, Germany. And assessing the option to conduct a study in the United States as well. Decision about USA location will be given within a few weeks.
    • 15 May 2017 New trial record
    • 08 May 2017 According to a Therapix Biosciences media release, this study is projected to be initiated during the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top